biote (BTMD) Competitors $2.88 -0.04 (-1.37%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.91 +0.03 (+0.90%) As of 08/8/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTMD vs. ZYME, AKBA, MLYS, TRVI, LENZ, NRIX, URGN, NUVB, SION, and SNDXShould you be buying biote stock or one of its competitors? The main competitors of biote include Zymeworks (ZYME), Akebia Therapeutics (AKBA), Mineralys Therapeutics (MLYS), Trevi Therapeutics (TRVI), LENZ Therapeutics (LENZ), Nurix Therapeutics (NRIX), Urogen Pharma (URGN), Nuvation Bio (NUVB), Sionna Therapeutics (SION), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. biote vs. Its Competitors Zymeworks Akebia Therapeutics Mineralys Therapeutics Trevi Therapeutics LENZ Therapeutics Nurix Therapeutics Urogen Pharma Nuvation Bio Sionna Therapeutics Syndax Pharmaceuticals biote (NASDAQ:BTMD) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Does the media favor BTMD or ZYME? In the previous week, biote had 9 more articles in the media than Zymeworks. MarketBeat recorded 13 mentions for biote and 4 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.87 beat biote's score of 0.20 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend BTMD or ZYME? biote presently has a consensus price target of $6.00, indicating a potential upside of 108.33%. Zymeworks has a consensus price target of $21.00, indicating a potential upside of 74.71%. Given biote's higher probable upside, research analysts plainly believe biote is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has more volatility and risk, BTMD or ZYME? biote has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Is BTMD or ZYME more profitable? biote has a net margin of 15.73% compared to Zymeworks' net margin of -182.75%. biote's return on equity of -19.71% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets biote15.73% -19.71% 17.83% Zymeworks -182.75%-23.00%-18.04% Which has preferable earnings & valuation, BTMD or ZYME? biote has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$197.19M0.80$3.16M$0.903.20Zymeworks$93.38M8.97-$118.67M-$1.49-8.07 Do insiders and institutionals believe in BTMD or ZYME? 21.7% of biote shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 24.0% of biote shares are owned by insiders. Comparatively, 1.9% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Summarybiote beats Zymeworks on 10 of the 17 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$159.75M$10.57B$5.44B$9.61BDividend YieldN/A2.01%4.61%4.14%P/E Ratio3.2019.8629.7524.84Price / Sales0.8021.90449.1298.65Price / Cash3.8121.7436.4258.36Price / Book-1.042.858.185.64Net Income$3.16M$211.77M$3.26B$265.68M7 Day Performance-25.96%3.65%6.88%4.95%1 Month Performance-30.10%2.67%1.00%0.83%1 Year Performance-47.54%-9.41%28.85%22.18% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote2.8038 of 5 stars$2.88-1.4%$6.00+108.3%-57.5%$159.75M$197.19M3.20194News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionZYMEZymeworks3.2559 of 5 stars$13.46+1.0%$21.00+56.0%+17.8%$937.93M$93.38M-8.97460News CoverageEarnings ReportAKBAAkebia Therapeutics3.9483 of 5 stars$3.59+0.8%$6.75+88.0%+187.4%$934.98M$160.18M-17.09430News CoverageMLYSMineralys Therapeutics2.1321 of 5 stars$13.60-5.0%$32.25+137.1%+16.4%$933.31MN/A-3.6528Upcoming EarningsTRVITrevi Therapeutics3.1732 of 5 stars$7.64-2.9%$20.88+173.2%+165.0%$923.10MN/A-16.9820News CoverageEarnings ReportAnalyst ForecastLENZLENZ Therapeutics1.659 of 5 stars$31.51-0.3%$48.60+54.2%+43.8%$889.98MN/A-17.80110News CoverageUpcoming EarningsNRIXNurix Therapeutics2.3512 of 5 stars$11.93+3.6%$29.31+145.7%-51.2%$880.69M$88.38M-4.57300Positive NewsURGNUrogen Pharma4.604 of 5 stars$18.90-0.3%$32.86+73.8%+18.4%$875.52M$90.40M-5.94200Trending NewsEarnings ReportAnalyst ForecastGap UpNUVBNuvation Bio1.9948 of 5 stars$2.55+2.0%$7.17+181.0%-20.1%$850.66M$7.87M-1.0960News CoverageEarnings ReportAnalyst ForecastGap UpSIONSionna TherapeuticsN/A$19.85+3.9%$38.50+94.0%N/A$842.78MN/A0.0035Positive NewsLockup ExpirationSNDXSyndax Pharmaceuticals4.2154 of 5 stars$9.57-0.6%$34.10+256.3%-37.6%$828.64M$23.68M-2.48110Earnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Zymeworks Alternatives Akebia Therapeutics Alternatives Mineralys Therapeutics Alternatives Trevi Therapeutics Alternatives LENZ Therapeutics Alternatives Nurix Therapeutics Alternatives Urogen Pharma Alternatives Nuvation Bio Alternatives Sionna Therapeutics Alternatives Syndax Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTMD) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTMD Stock Alerts